{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:47:52Z","timestamp":1785754072937,"version":"3.56.0"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Assessment at progression after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy in EGFR-mutant non-small cell lung cancer requires more than identifying a single resistance mechanism. It also requires attention to lineage plasticity, tumor heterogeneity, the pattern of progression, and tissue-based findings. In a subset of patients, rebiopsy may reveal squamous histological transformation, sometimes with retention of the founder EGFR mutation. When present, retention of the founder EGFR mutation supports a shared clonal origin but does not, by itself, determine treatment. Confirmation of squamous transformation also changes the evidentiary context, because results from histologically unselected post-EGFR-TKI populations cannot always be applied directly to patients with confirmed transformation. This review focuses on squamous transformation and related basal\/squamous reprogramming detected at EGFR-TKI progression, with particular emphasis on histological and molecular reassessment. We distinguish between direct clinical evidence from histologically confirmed transformed tumors and supportive translational evidence from EGFR-mutant resistance models and related lineage-transition systems. Plasma circulating tumor DNA can identify selected resistance alterations and track molecular evolution, but it cannot define morphology or lineage identity. When transformation is suspected, repeat tissue biopsy remains central, and reassessment should integrate morphology, immunohistochemistry, and paired molecular comparison with the original tumor. Integrated pathological and molecular reassessment may also uncover coexisting actionable alterations and help clarify whether progression is driven mainly by the transformed component, residual EGFR-dependent disease, or mixed resistance. Current evidence does not support a transformation-specific treatment sequence, so management remains individualized. Future studies should combine prospective rebiopsy cohorts, paired tissue\u2013plasma profiling, and clinically annotated models to identify predictors of transformation and develop lineage-informed treatment strategies.<\/jats:p>","DOI":"10.3389\/fonc.2026.1910407","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:20:58Z","timestamp":1785752458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Squamous transformation of EGFR-mutant lung adenocarcinoma after EGFR-TKI therapy: clonal continuity, tissue-based diagnosis, and therapeutic evidence gaps"],"prefix":"10.3389","volume":"16","author":[{"given":"Lijiang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shenyang Tenth People\u2019s Hospital","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Oncology Department of Integrated Traditional Chinese and Western Medicine, Shenyang Tenth People\u2019s Hospital","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shenyang Tenth People\u2019s Hospital","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.275","article-title":"Genomic staging of multifocal lung squamous cell carcinomas is independent of the comprehensive morphologic assessment","volume":"19","author":"Dacic","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/nejmoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: Clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.05.006","article-title":"Current knowledge of small cell lung cancer transformation from non-small cell lung cancer","volume":"94","author":"Giaccone","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103044","article-title":"Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming","volume":"141","author":"Wang","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.11.016","article-title":"Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case","volume":"127","author":"Roca","year":"2019","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6870","article-title":"Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer","volume":"13","author":"Lin","year":"2024","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02475-9","article-title":"Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies","volume":"130","author":"Leonetti","year":"2024","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-025-01180-x","article-title":"Lineage plasticity and histological transformation: tumor histology as a spectrum","volume":"35","author":"Li","year":"2025","journal-title":"Cell Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-1866","article-title":"Histologic transformation in cancer: The path for clinical translation","volume":"15","author":"Vathiotis","year":"2025","journal-title":"Cancer Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.012","article-title":"Molecular landscape and therapeutic strategies of lung cancer lineage plasticity","volume":"20","author":"Banerjee","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-1067","article-title":"Lineage plasticity: The new cancer hallmark on the block","volume":"84","author":"Mehta","year":"2024","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2022.02.006","article-title":"Histologic transformation of epidermal growth factor receptor-mutated lung cancer","volume":"166","author":"Fujimoto","year":"2022","journal-title":"Eur J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12967-025-07540-w","article-title":"Clinicopathologic features and therapeutic outcomes in EGFR\/ALK-aberrations NSCLC with histologic transformation","volume":"24","author":"Ding","year":"2026","journal-title":"J Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","article-title":"Best practices recommendations for diagnostic immunohistochemistry in lung cancer","volume":"14","author":"Yatabe","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2019.05.024","article-title":"Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma","volume":"134","author":"Park","year":"2019","journal-title":"Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-1515","article-title":"Eradicating drug-tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy","volume":"15","author":"Baldacci","year":"2025","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.01.005","article-title":"Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition","volume":"105","author":"Le","year":"2017","journal-title":"Lung Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16192","article-title":"Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms","volume":"115","author":"Shiba-Ishii","year":"2024","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2025.152478","article-title":"Clinicopathologic features of histologic transformation in lung adenocarcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitors","volume":"77","author":"Song","year":"2025","journal-title":"Ann Diagn Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae392","article-title":"Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic target","volume":"11","author":"Wang","year":"2024","journal-title":"Natl Sci Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1038\/s41467-025-59623-3","article-title":"Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma","volume":"16","author":"Shinozaki","year":"2025","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107895","article-title":"Treatment sequences in EGFR mutant advanced NSCLC","volume":"194","author":"Wespiser","year":"2024","journal-title":"Lung Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41698-023-00430-8","article-title":"Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma","volume":"7","author":"Zhao","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aea4881","article-title":"Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation","volume":"18","author":"Dymun","year":"2026","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70458","article-title":"Persistent lineage plasticity driving lung cancer development and progression","volume":"15","author":"Meng","year":"2025","journal-title":"Clin Transl Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccell.2020.06.012","article-title":"Emergence of a high-plasticity cell state during lung cancer evolution","volume":"38","author":"Marjanovic","year":"2020","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09985-x","article-title":"Critical role for a high-plasticity cell state in lung cancer","volume":"651","author":"Chan","year":"2026","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-0111","article-title":"AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer","volume":"12","author":"Noronha","year":"2022","journal-title":"Cancer Discov"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/s41467-021-21884-z","article-title":"Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer","volume":"12","author":"Aissa","year":"2021","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-0438","article-title":"ASCL1 drives tolerance to osimertinib in EGFR mutant lung cancer in permissive cellular contexts","volume":"84","author":"Hu","year":"2024","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4607","article-title":"Integrative profiling of T790M-negative EGFR-mutated NSCLC reveals pervasive lineage transition and therapeutic opportunities","volume":"27","author":"Chua","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13045-021-01186-z","article-title":"Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation","volume":"14","author":"Quintanal-Villalonga","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-025-01657-7","article-title":"KMT2D loss drives adeno-to-squamous transition and sensitizes TKI-resistant lung cancer to AURKA inhibition","volume":"33","author":"Chen","year":"2026","journal-title":"Cell Death Differ"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.molcel.2025.03.001","article-title":"Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma","volume":"85","author":"Pulice","year":"2025","journal-title":"Mol Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer","volume":"41","author":"de Miguel","year":"2023","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41594-025-01685-4","article-title":"Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification","volume":"33","author":"Starble","year":"2026","journal-title":"Nat Struct Mol Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.devcel.2024.10.009","article-title":"FoxA1\/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma","volume":"60","author":"Gillis","year":"2025","journal-title":"Dev Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-2540","article-title":"Overcoming Osimertinib resistance with AKT inhibition in EGFRm-driven non-small cell lung cancer with PIK3CA\/PTEN alterations","volume":"30","author":"Grazini","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ejca.2024.114895","article-title":"Genome-wide CRISPR screens identify the YAP\/TEAD axis as a driver of persister cells in EGFR mutant lung cancer","volume":"7","author":"Pfeifer","year":"2024","journal-title":"Commun Biol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwad028","article-title":"Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment","volume":"10","author":"Tang","year":"2023","journal-title":"Natl Sci Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.653","article-title":"Cancer-associated fibroblast-derived colony-stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis","volume":"5","author":"Huang","year":"2024","journal-title":"MedComm"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41392-025-02481-8","article-title":"A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib","volume":"10","author":"Shi","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-25-0960","article-title":"ELIOS: A multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung cancer treated with first-line osimertinib","volume":"16","author":"Piotrowska","year":"2026","journal-title":"Cancer Discov"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.052","article-title":"Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer","volume":"148","author":"Lee","year":"2021","journal-title":"Eur J Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-1022","article-title":"Landscape of acquired resistance to Osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with Osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"key":"B69","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3322\/caac.70024","article-title":"Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","article-title":"Single-cell and spatial transcriptomics analysis of non-small cell lung cancer","volume":"15","author":"De Zuani","year":"2024","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-20-2811","article-title":"Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer","volume":"81","author":"Kashima","year":"2021","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012374","article-title":"Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor","volume":"13","author":"Bang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221130503","article-title":"Histologic transformation in lung cancer: When one door shuts, another opens","volume":"14","author":"Sato","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251369038","article-title":"Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: Mechanisms and therapeutic challenges","volume":"17","author":"Li","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184641","article-title":"Histologic transformation in EGFR-mutant lung adenocarcinomas: Mechanisms and therapeutic implications","volume":"13","author":"Pathak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.106027","article-title":"Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer","volume":"11","author":"Le","year":"2026","journal-title":"ESMO Open"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1274","article-title":"Nongenetic evolution drives lung adenocarcinoma spatial heterogeneity and progression","volume":"11","author":"Tavernari","year":"2021","journal-title":"Cancer Discov"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02230-w","article-title":"Evolutionary characterization of lung adenocarcinoma morphology in TRACERx","volume":"29","author":"Karasaki","year":"2023","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05706-4","article-title":"Genomic-transcriptomic evolution in lung cancer and metastasis","volume":"616","author":"Mart\u00ednez-Ruiz","year":"2023","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232028","article-title":"EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation","volume":"221","author":"Qin","year":"2024","journal-title":"J Exp Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0289","article-title":"Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma","volume":"14","author":"Li","year":"2024","journal-title":"Cancer Discov"},{"key":"B82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: Tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05729-x","article-title":"The evolution of non-small cell lung cancer metastases in TRACERx","volume":"616","author":"Al Bakir","year":"2023","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189413","article-title":"Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches","volume":"1880","author":"Liu","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110462","article-title":"Prevalence of histological transformation in first-line Osimertinib non-small cell lung cancers: Case series and literature review","volume":"26","author":"Sparavelli","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.005","article-title":"Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors","volume":"42","author":"Tirosh","year":"2024","journal-title":"Cancer Cell"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Fran\u00e7a","year":"2024","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112212","article-title":"Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma","volume":"42","author":"Ebisudani","year":"2023","journal-title":"Cell Rep"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100911","article-title":"Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study","volume":"4","author":"Wang","year":"2023","journal-title":"Cell Rep Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41419-024-06940-y","article-title":"Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer","volume":"15","author":"Izumi","year":"2024","journal-title":"Cell Death Dis"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:20:59Z","timestamp":1785752459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":93,"alternative-id":["10.3389\/fonc.2026.1910407"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1910407","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1910407"}}